Amarin Corp Plc (AMRN)

[DMC8]

Reminder

If the LR-ETEPA patent is granted, it would support (indirectly) the oncology indication explored in the EMT2 trial, primarily through enabling a superior proprietary formulation with demonstrably better absorption and tissue delivery of EPA. It does not directly alter or “help run” the EMT2 trial itself, which is already using standard plain EtEPA (icosapent ethyl / Vascepa). Here’s the breakdown based on the patent details and trial context.

What is LR-ETEPA?
• LR-ETEPA stands for lymph-releasing eicosapentaenoic acid ethyl ester. It is Amarin Pharmaceuticals’ patented (pending) formulation that combines EtEPA (the active in Vascepa) with phospholipids (1–85% by weight) and optional emulsifiers.

• The key innovation is lymphatic routing: it preferentially delivers EPA via the lymphatic system instead of the portal vein. This avoids heavy first-pass hepatic metabolism and visceral adipose sequestration, leading to higher systemic and tissue EPA levels.
Better Absorption? Yes — Preclinical Data Shows Clear Superiority

• At equimolar doses of EtEPA:
? Lymph EPA levels: 2.4× higher vs. plain EtEPA.
? Key tissues: lungs (1.7×), heart (2.0×), brain (1.7×), alveolar macrophages (significant increase).
? EPA/AA ratios (anti-inflammatory marker) also rise substantially (e.g., 2.6× in lungs).
• It explicitly claims superior EPA uptake and potency, meaning potentially lower dosing for equivalent (or better) tissue enrichment.0
• The patent explicitly lists cancer among treatable/preventable diseases (alongside cardiovascular, renal, neurological, etc.), tying improved delivery to broader therapeutic potential.2
Connection to EMT2 Trial (Oncology Indication)
• EMT2 (NCT03428477) is an independent Phase 3, randomized, placebo-controlled trial (University of Leeds-sponsored, ~448 patients) testing plain EtEPA/Vascepa (4 g daily) in patients undergoing curative liver resection for colorectal cancer liver metastases. Primary endpoint: progression-free survival (PFS) / reduced recurrence. It is not using LR-ETEPA; the trial protocol and drug supply use standard icosapent ethyl.11
• Patent approval does NOT change EMT2 results — the trial data will stand or fall on the plain EtEPA formulation (results still pending as of latest updates).
• However, it helps the overall oncology indication strategically (especially for Amarin):
? If EMT2 is positive, Amarin could pursue an sNDA/label expansion using the LR-ETEPA version as a next-generation product with superior bioavailability/tissue targeting.
? The patent provides IP protection (composition + methods of use for cancer) for this improved formulation, extending exclusivity and commercial value beyond plain EtEPA generics.
? Investor analyses (Amarin context) explicitly view LR-ETEPA patent issuance + EMT2 readout as paired catalysts for oncology market expansion and potential M&A/valuation upside.

Patent Status (as of now)
• WO2023146984A1 (PCT, published Aug 2023) + corresponding US application (18/472,875) are pending (not yet granted). National filings (e.g., KR) exist; examination is ongoing.

• “If approved” = grant would lock in the above advantages.

Bottom line: The patent approval itself delivers better absorption (proven in preclinical lymph/tissue data) and a protectable next-gen formulation. It does not retroactively boost the EMT2 trial data (which uses plain EtEPA), but it strengthens Amarin’s position to commercialize an oncology indication if EMT2 succeeds — by offering a differentiated, higher-potency EPA product with cancer-specific use claims. This is why it is discussed as a key pipeline catalyst in Amarin-related analyses.